Clarivate Plc, a global leader facilitating the connection of individuals and organizations with reliable intelligence to revolutionize their world, has unveiled its annual Drugs to Watch™ report. This report offers in-depth predictive analysis of drugs anticipated to achieve notable commercial and clinical success. Renowned as a pivotal resource in the evolving healthcare landscape, the report has identified over 85 Drugs to Watch during its 11-year existence.
In the current release, analysts have pinpointed 13 novel therapeutics and drugs set to launch in 2024. According to Clarivate’s predictive analytics, these drugs have the potential to attain blockbuster status by 2029 or bring transformative benefits to patients. The highlighted advancements cover a diverse range of therapeutic innovations, including treatments for breast cancer, hemophilia A, sickle cell disease, Crohn’s disease, ulcerative colitis, respiratory syncytial virus (RSV), and multiple myeloma.
Moreover, the report sheds light on the expanding chronic disease market in Mainland China, spotlighting seven drugs expected to achieve $1 billion blockbuster status by 2029 or significantly impact Chinese patients seeking improved treatment options.
Mike Ward, Global Head of Thought Leadership, Life Sciences and Healthcare at Clarivate, expressed optimism about the robust fundamentals supporting the biopharma sector. He emphasized the role of new technologies in driving medical advancements and expanding treatment options for patients with unmet needs. Leveraging industry expertise and comprehensive data, the Drugs to Watch report identifies innovative medicines poised to make extraordinary impacts on patient outcomes based on recent scientific breakthroughs.
The year 2024 is anticipated as a transformative period for pharmaceutical innovation, with modalities like antibody drug conjugates and AI/machine learning achieving clinical successes. Despite these positive trends, external factors such as government healthcare cost containment initiatives, sustained high capital costs, and global geopolitical disputes are adversely affecting investor interest in the sector.
The 2024 Drugs to Watch report highlights significant trends that will influence the discovery, development, and delivery of new medicines. It spotlights drugs and drug candidates expected to achieve crucial milestones in the coming years, establishing themselves as either blockbuster or breakthrough medicines.
The Drugs to Watch for 2024 include:
- Aflibercept (high dose; EYLEA® HD) by Bayer and Regeneron Pharmaceuticals Inc
- Budesonide (TARPEYO®/Kinpeygo®/Nefecon) by Calliditas Therapeutics AB, Everest Medicines, and STADA Arzneimittel AG
- Datopotamab deruxtecan (Dato-DXd) by AstraZeneca and Daiichi Sankyo
- Efanesoctocog alfa (ALTUVIIIO™/BIVV001) by Sanofi (Bioverativ Therapeutics Inc) and Swedish Orphan Biovitrum AB (Sobi®)
- Ensifentrine (RPL554) by Verona Pharma
- Exagamglogene autotemcel (CASGEVY™/exa-cel) and lovotibeglogene autotemcel (LYFGENIA™/lovo-cel/formerly LentiGlobin™) by CRISPR Therapeutics, Vertex Pharmaceuticals Inc (exa-cel), and Bluebird Bio (lovo-cel)
- Mirikizumab (Omvoh™/LY-3074828) by Eli Lilly and Company
- Niraparib + abiraterone acetate (AKEEGA™) by Johnson & Johnson Innovative Medicine
- RSVpreF (ABRYSVO™/PF-06928316) and RSVpreF3 (AREXVY/GSK-3844766A) by Pfizer Inc (ABRYSVO) and GSK plc (AREXVY)
- Talquetamab (TALVEY™) by Johnson & Johnson Innovative Medicine
- Zolbetuximab (IMAB362) by Astellas Pharma Inc
The report also emphasizes new technology platforms, such as CRISPR-Cas9 gene editing and artificial intelligence (AI)/machine learning (ML) tool applications, expected to demonstrate significant proof of medical use in the market in 2024. These technologies hold the potential to reduce costs and expedite innovation cycles, enabling the quicker delivery of innovative drugs to patients in the future.
